文献速递脑血管病

美国心房颤动合并脑出血幸存者抗凝与左心耳封堵的当代实践模式

Contemporary US Practice Patterns Regarding Anticoagulation and LAA Closure in ICH Survivors With Atrial Fibrillation
RSS 订阅 · Stroke

结果显示出院后5年累积抗凝治疗率为59.8%,抗血小板治疗率为39.9%,左心耳封堵率仅4.5%,提示临床实践差异大。

要点

  • 脑出血合并房颤患者出院后5年累积抗凝率59.8%,抗血小板率39.9%。
  • 左心耳封堵使用率低,5年累积仅4.5%,且不随年份变化。
  • 多数患者出院后接受抗凝或仅抗血小板治疗,策略差异广泛。

核心结论

  • 在美国当代多中心队列中,脑出血合并房颤患者出院后约60%接受抗凝治疗,其余多仅用抗血小板治疗。
  • 左心耳封堵使用率很低,5年累积仅4.5%,且不随索引脑出血日期变化。

研究设计与样本

  • 基于TriNetX Linked平台关联电子健康记录、药房和保险理赔数据的研究。
  • 纳入2016至2024年因脑出血住院的成人房颤患者2276例。
  • 采用Kaplan-Meier统计计算从出院至5年的治疗累积使用率,并设置3个互斥治疗组进行删失分析。

主要发现

  • 2276例患者平均年龄65.4(±12.8)岁,女性占40.6%。
  • 中位CHA2DS2-VASc评分为5(四分位距5–6),19.6%有Medicare保险。
  • 26.9%在脑出血前90天内接受过抗凝处方,半数出院回家或转至急性康复机构。
  • 5年累积抗凝率为59.8%(95%CI 55.5%–64.2%)。
  • 5年累积抗血小板治疗率为39.9%(95%CI 34.1%–46.3%),左心耳封堵率为4.5%(95%CI 2.6%–7.6%)。

临床怎么用

  • 美国实践中脑出血合并房颤患者出院后多数接受抗凝或仅抗血小板治疗,左心耳封堵应用极少。
  • 临床决策需权衡缺血与出血风险,当前实践差异大,缺乏统一标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Stroke, Ahead of Print. BACKGROUND:Optimal secondary stroke prevention remains uncertain for patients with intracerebral hemorrhage (ICH) and atrial fibrillation (AF). Anticoagulation reduces ischemic stroke in AF but increases hemorrhage. Left atrial appendage (LAA) occlusion is emerging as an alternative to anticoagulation, but few data exist on its safety in patients with ICH. Amid this uncertainty, little is known about US practice patterns in this scenario.METHODS:We performed a study using linked electronic health record, pharmacy, and insurance claims data on >11 million patients at 29 US healthcare organizations, each with multiple hospital sites, in the TriNetX Linked platform. ValidatedInternational Classification of Diseases, Tenth Revisioncodes were used to identify adults with AF hospitalized for ICH during 2016 to 2024. To identify antiplatelet and anticoagulant prescriptions, we used RxNorm codes, a standardized drug naming system from the National Library of Medicine. LAA occlusion was defined using validatedCurrent Procedural Terminologycodes. Kaplan-Meier statistics were used to calculate cumulative rates of therapy utilization from discharge through 5 years. We created 3 mutually exclusive treatment groups with censoring at LAA occlusion for analyses of antiplatelet and anticoagulant therapy and at anticoagulation for analyses of antiplatelet therapy.RESULTS:We identified 2276 patients with AF hospitalized with ICH. Their mean age was 65.4 (±12.8) years, 40.6% were female, median CHA2DS2-VASc score was 5 (interquartile range, 5–6), 19.6% had Medicare, 26.9% received an anticoagulant prescription within 90 days before ICH, and half were discharged home or to an acute rehabilitation facility. Cumulative 5-year rates were 59.8% (95% CI, 55.5%–64.2%) for anticoagulation, 39.9% (95% CI, 34.1%–46.3%) for antiplatelet therapy, and 4.5% (95% CI, 2.6%–7.6%) for LAA occlusion. LAA occlusion rates did not differ by index ICH date (P=0.88).CONCLUSIONS:In a contemporary, multicenter US cohort of patients with ICH and AF, 60% were prescribed anticoagulation after discharge, and the remainder were mostly treated with antiplatelet therapy only. These findings suggest widespread use of different secondary stroke prevention strategies in patients with AF and ICH.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Stroke:Contemporary US Practice Patterns Regarding Anticoagulation and LAA Closure in ICH Survivors With Atrial Fibrillation

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。